Repligen (RGEN) Set to Announce Earnings on Tuesday

Repligen (NASDAQ:RGEN) will be releasing its earnings data before the market opens on Tuesday, July 30th. Analysts expect Repligen to post earnings of $0.33 per share for the quarter. Repligen has set its FY24 guidance at $1.42-1.49 EPS and its FY 2024 guidance at 1.420-1.490 EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same quarter in the previous year, the business posted $0.64 earnings per share. Repligen’s revenue was down 17.1% on a year-over-year basis. On average, analysts expect Repligen to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Trading Up 6.4 %

Shares of Repligen stock opened at $140.79 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. Repligen has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a market capitalization of $7.87 billion, a P/E ratio of 563.18, a P/E/G ratio of 4.71 and a beta of 0.95. The business has a 50 day moving average price of $135.47 and a 200 day moving average price of $166.50.

Insider Buying and Selling at Repligen

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at approximately $27,456,162.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Martin D. Madaus purchased 1,615 shares of the business’s stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the acquisition, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and cut their price objective for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. JPMorgan Chase & Co. cut their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Finally, Guggenheim assumed coverage on Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $194.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.